Drug
Efanesoctocog Alfa
Efanesoctocog Alfa: highest development phase Post-Market, developed by Sanofi, Swedish Orphan Biovitrum. 6 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Sanofi, Swedish Orphan Biovitrum
Trials
| Drug | Phase | Indication |
|---|---|---|
| Efanesoctocog alfa NCT06941870 | Post-Market | Factor VIII Deficiency |
| Efanesoctocog alfa NCT06940830 | Post-Market | Hemophilia A |
| Efanesoctocog alfa NCT06752850 | Post-Market | Haemophilia A (Moderate or Severe) |
| Efanesoctocog alfa NCT05817812 | Phase 3 | Hemophilia A, Severe |
| Efanesoctocog alfa NCT06716814 | Phase 3 | Haemophilia A (Moderate or Severe) |
| Efanesoctocog alfa NCT06579144 | Phase 1 | Hemophilia A |
Latest
No recent events.
Follow Efanesoctocog Alfa on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.